Open Access

Target volume dose and clinical outcome in radiotherapy for primary marginal zone lymphoma of the ocular adnexa

  • Authors:
    • Natuhiko Shirota
    • Hidetsugu Nakayama
    • Sachica Shiraishi
    • Yoshihiko Usui
    • Keisuke Kimura
    • Tomohide Sanada
    • Norifumi Kennoki
    • Mitsuru Okubo
    • Hiroshi Goto
    • Koichi Tokuuye
  • View Affiliations

  • Published online on: May 5, 2017     https://doi.org/10.3892/mco.2017.1241
  • Pages: 833-838
  • Copyright: © Shirota et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to determine the optimal dose and optimal target volume for marginal zone lymphoma of the ocular adnexa. Between January, 2008 and December, 2013, 40 patients with histologically proven primary marginal zone lymphoma of the ocular adnexa who underwent radiotherapy at the Tokyo Medical University were evaluated. The prescribed dose was 30 Gy in 15 fractions to the iso‑center. Doses to the gross tumor volume (GTV), conjunctiva, bulbus oculi, retina and retrobulbar space were investigated, and the association between dose‑volume factors and clinical outcome was analyzed. The overall and local progression‑free survival rates at 3 and 5 years were 100% during a median observation period of 32 months. Two patients relapsed in the contralateral ocular adnexa. The progression‑free survival rates at 3 and 5 years were 100 and 93.3%, respectively. The mean dose was 2.0 and 1.9 Gy for targets receiving 95% of the GTV dose (D95). The minimum dose was 0.9‑2.0 Gy (median, 1.8 Gy). Thus, primary marginal zone lymphoma of the ocular adnexa favorably responded to lower doses of radiation, compared with prescribed doses to the iso‑center. A radiation dose of 27 Gy in 15 fractions at D95 of GTV appeared to be optimal.
View Figures
View References

Related Articles

Journal Cover

June-2017
Volume 6 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shirota N, Nakayama H, Shiraishi S, Usui Y, Kimura K, Sanada T, Kennoki N, Okubo M, Goto H, Tokuuye K, Tokuuye K, et al: Target volume dose and clinical outcome in radiotherapy for primary marginal zone lymphoma of the ocular adnexa. Mol Clin Oncol 6: 833-838, 2017
APA
Shirota, N., Nakayama, H., Shiraishi, S., Usui, Y., Kimura, K., Sanada, T. ... Tokuuye, K. (2017). Target volume dose and clinical outcome in radiotherapy for primary marginal zone lymphoma of the ocular adnexa. Molecular and Clinical Oncology, 6, 833-838. https://doi.org/10.3892/mco.2017.1241
MLA
Shirota, N., Nakayama, H., Shiraishi, S., Usui, Y., Kimura, K., Sanada, T., Kennoki, N., Okubo, M., Goto, H., Tokuuye, K."Target volume dose and clinical outcome in radiotherapy for primary marginal zone lymphoma of the ocular adnexa". Molecular and Clinical Oncology 6.6 (2017): 833-838.
Chicago
Shirota, N., Nakayama, H., Shiraishi, S., Usui, Y., Kimura, K., Sanada, T., Kennoki, N., Okubo, M., Goto, H., Tokuuye, K."Target volume dose and clinical outcome in radiotherapy for primary marginal zone lymphoma of the ocular adnexa". Molecular and Clinical Oncology 6, no. 6 (2017): 833-838. https://doi.org/10.3892/mco.2017.1241